The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2019 | NSCLC: a treatment landscape in flux in the checkpoint inhibitor era
The treatment landscape of non-small cell lung cancer (NSCLC) is in a state of flux, with novel immuno-oncology agents and combinations at the forefront. Here, Martin Reck, MD, PhD, from Lung Clinic Grosshansdorf, Grosshansdorf, Germany, gives his insight into this changing field and the future considerations. This interview took place at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.
